MINUTES

CPIC CONFERENCE CALL

DATE: October 6, 2011

PRESENT:

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Update of PharmGKB site (tutorial files attached) | Teri demonstrated improvements to the PharmGKB site. Many additions have been made to add further clinical information. See the clinical interpretations box on the front page of PharmGKB. | CPIC members should provide Teri and the PharmGKB team feedback on how to continue to make PharmGKB useful to clinicians. |
| Possibility of IL28B/interferon guidelines  | There was some discussion of whether this gene/drug pair has sufficiently concrete enough recommendations to warrant a CPIC guideline. There was a conference call with Mary Relling, David Goldstein, and Andrew Muir.The discussion was who would be willing to assist with writing this guideline. Julie Johnson has a colleague (head of CTSA) who is a hepatology expert. She will contact him for feedback. Others also have contacts who are hep C experts who they will contact to see if it is the right time for guidelines.  | CPIC members to provide feedback to the group on upcoming calls.Drs. Muir/Goldstein will follow-up on their interest in possibly leading the guidelines. |
| Updates on guidelines in progress  | -- CYP2D6 and Codeine is in review; could be out in February -- Abacavir guidelines about to be submitted to CPT, which puts it on track for Spring 2012 publication -- Allopurinol group just starting -- Carbamazepine/HLA – under work with Susan Leckband and others-- Other guidelines to work on next?-- Kevin Hicks interested in CYP2D6 and amitriptyline—have been discussing with Jesse Swen and Dutch group. Discussion on how/whether to combine antidepressant drugs –  -- Discussion would be that overall it would be better to do as a class; for example do all antidepressants and not just amitriptyline; however, this could get complex as the specifics are considered further (paroxetine example)  | Revisit discussion of antidepressants at November call to determine best approach for CYP2D6 and prioritize all guidelines. |
| Posting gene/drug pair list on public section of PharmGKB | Issam Zineh from FDA He works on FDA label changes to include pgen information and has questions for our group1. How is the updated pgen label information used? (PharmGKB, PGRN, CPIC)

Teri – feed into PharmGKB; helps with prioritization of CPIC guidelines; from PGRN standpoint information is also useful However, important to note that PGRN cannot necessarily go along exactly with what FDA says  Warfarin discussion Julie stated there sometimes may be differences of opinion with the specifics of label changes vs. CPIC guidelines – warfarin examples1. How can Issam go back and justify label changes?

It is important not to hinder research; there is always more that can be learned  -- encourage need to stay open to changes Others noted that FDA action has prompted discussion on pgen that may not have occurred otherwise CPIC add more detail to the label information at PharmGKB | Overall want to encourage and coordinate efforts between FDA/CPIC/PGRN |